239 results
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
in the field of retinitis pigmentosa and/or any other disease in ophthalmology.
We will be primarily responsible for the design and implementation of clinical … development of KIO-301 through phase 2, for which we will be reimbursed by TOI subject to a maximum amount. TOI will be responsible at its own cost
8-K
EX-99.1
sohjndaog7 flcy97
25 Mar 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
38ua7t ow5a1
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
EX-10.1
o1j zo1j9t3c7hf
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.3
quzwfgkmtdxp iah2ee8
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.2
ysixxmum
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.1
70rpv5x
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-99.1
4ej27m5 r3prx
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
i8v9 wzeks3
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
l1dtce
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm